Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with primary aldosteronism, which is the most prevalent form of secondary hypertension, have an increased rate of cardiovascular events, compared to patients with essential hypertension, even with equal severity of hypertension. This might be partially attributed to the association of increased aldosterone levels with insulin resistance. How this relation can be explained from a pathophysiological point of view, is insufficiently established.
Recently, microvascular dysfunction has been proposed as a link between insulin resistance and hypertension. Loss of NO-mediated vasodilation is an important feature of microvascular dysfunction; in addition, an impaired insulin-mediated microvascular NO production has been suggested to underlie the reduction in insulin-stimulated glucose disposal that is characteristic of insulin-resistant states. Increased aldosterone levels are not only associated with insulin resistance, but also with endothelial dysfunction. In addition, they interfere with the vascular effects of insulin.
Therefore, the investigators hypothesize that in patients with primary aldosteronism, increased aldosterone levels induce microvascular dysfunction through reduction of NO-availability, which contributes to the development of insulin resistance, and of hypertension, in addition to the sodium-retaining effects of aldosterone.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary aldosteronism | Patients with primary aldosteronism, who undergo surgery or will be started on antihypertensive medication, including mineralocorticoid receptor antagonists |
| |
| Essential hypertension | Patients with essential hypertension who will be started on antihypertensive medication |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Adrenal extirpation | Procedure |
| ||
| Antihypertensive medication |
| Measure | Description | Time Frame |
|---|---|---|
| Microvascular recruitment in skeletal muscle during hyperinsulinaemia | Baseline | |
| Microvascular recruitment in skeletal muscle during hyperinsulinaemia | 3 months after (initiation of) treatment |
Not provided
Not provided
Inclusion Criteria:
Patients with primary aldosteronism
Patients with essential hypertension
Exclusion Criteria:
Not provided
Not provided
Twenty patients with primary aldosteronism and twenty patients with essential hypertension
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Prof. C.D.A. Stehouwer, MD, PhD | Maastricht University Hospital | Principal Investigator |
Not provided
| ID | Term |
|---|---|
| D006929 | Hyperaldosteronism |
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D000308 | Adrenocortical Hyperfunction |
| D000307 | Adrenal Gland Diseases |
| D004700 | Endocrine System Diseases |
| D006973 | Hypertension |
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |